Docetaxel and Prednisone ± Enzalutamide as First-Line Treatment in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Docetaxel and Prednisone With or Without Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: CHEIRON, a Randomised Phase II Trial
Eur. J. Cancer 2021 Aug 03;[EPub Ahead of Print], O Caffo, C Ortega, F Nolè, et alAdvanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.